- Bombshell development in the wearables market as Nike bows out (well, of the hardware side, anyway), putting the brakes on future Fuelband iterations amid speculation that they're clearing the way for a collaboration with Apple.
- A trio large pharmas traded units amid continued emphasis on narrowly focused portfolios. Novartis bought a pair of GSK cancer drugs to complement its Gleevec franchise, and in turn sold its vaccines business to GSK while also selling its animal health division to Lilly.
- For all the payer gnashing of teeth over Gilead's pricey hep C drug Sovaldi, so far, it's not crimping sales. The brand crushed analysts expectations for $1.13 billion in sales by more than a billion. However, several medical societies are starting to factor costs into treatment guidelines or are threatening to, anyway.
- There's now a whole medical scribe staffing industry to help physicians feed their EHRs in patient consults.
- Is Facebook dipping a toe in the fitness tracking market with its latest purchase
- The comments period for FDA's first draft guidance on social media closed, and Klick Health has an overview of the comments. The sore spots are the definitions of editorial control and influence.
- Nine out of ten Americans are willing to share their health data with researchers, but for most, it's conditional, and data privacy is a concern.
- Apple is embracing digital advertising in a big way for the first time after pursuing a TV-centric advertising strategy for its entire existence. Wait, what? Who says pharma's an old fuddy-duddy of an industry, anyway
- - See more at: http://healthandpharmainsight.tumblr.com/post/83842375761/in-case-you-missed-it#sthash.AjKFLjGO.dpuf
By Matthew Arnold, Principal Analyst
Does Facebook's pivot towards discrete single-function apps have implications for healthcare app developers The social giant's announcement that it will discontinue support for the chat function in its flagship product a prelude to a planned unbundling was doubtless motivated, in part, by a need to establish new revenue streams and fend off the pack of one-trick apps nipping at its heels. But it also reflects, in the words of one VC quoted by Wired, a vision of a mobile-centric world in which we see simple, clear, snackable experiences winning.
That may prove true, but many of the most popular health and fitness apps boast an array of features, and while pharma apps tend to be narrower in their functionality so far, there are those that offer a pretty rich menu of options (Janssen's Care4Today and Sanofi's pioneering GoMeals come to mind). The rule, if there is one, seems to be this: give consumers something useful that they can't find elsewhere.
Tougher than it sounds, given the cluttered state of app offerings for many conditions. But figuring it out may be rewarding, because apps from pharma are highly influential at all points in the care journey, as we learned in our most recent ePharma Consumer® report. Furthermore, though adoption is modest, these apps are disproportionately used by patients who have trouble staying adherent exactly the patients that need them most.